throbber
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`(19) World Intellectual Property Organization _
`International Bureau
`
`(43) International Publication Date
`
`7 February 2008 (07.02.2008)
`
` ' |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
`
`(10) International Publication Number
`
`WO 2008/015695 A2
`
`(51) International Patent Classification:
`A61K 47/40 (2006.01)
`A61K 31/335 (2006.01)
`
`(21) International Application Number:
`PCT/IN2007/000199
`
`(22) International Filing Date:
`
`15 May 2007 (15.05.2007)
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`(30) Priority Data:
`748/MUM/2006
`
`English
`
`English
`
`15 May 2006 (15.05.2006)
`
`IN
`
`(71) Applicant (for all designated States except US): SUN
`PHARMACEUTICAL
`INDUSTRIES
`LIMITED
`
`[TN/IN]; Acme Plaza, Andheri—Kurla Road, Andheri (e),
`Mumbai 400 059 (IN).
`
`(72) Inventors; and
`(75) Inventors/Applicants (for US only): BHOWMICK,
`Subhas, Balaram [TN/IN]; Sun Pharma Advanced Re—
`search Centre, Nima Compound, Near Pratham Enclave,
`Tandalja Road, Baroda 390 020 (IN). LADDHA, Ritu,
`Nitin [TN/IN]; Sun Pharma Advanced Research Centre,
`Nima Compound, Near Pratham Enclave, Tandalja Road,
`Baroda 390 020 (IN). KHOPADE, Surekha [IN/IN]; Sun
`Pharma Advanced Research Centre, Nima Compound,
`Near Pratham Enclave, Tandalja Road, Baroda 390 020
`(IN).
`
`(81) Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,
`CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
`FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN,
`IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR,
`LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX,
`MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
`RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
`TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
`
`(84) Designated States (unless otherwise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
`ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
`European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
`FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,
`PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
`GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
`
`Declarations under Rule 4.17:
`
`as to the identity of the inventor (Rule 4.1 7(i))
`as to applicant’s entitlement to apply for and be granted a
`patent (Rule 4.1 7(ii))
`as to the applicant’s entitlement to claim the priority of the
`earlier application (Rule 4.1 7(iii))
`of inventorship (Rule 4.17(iv))
`
`Published:
`
`without international search report and to be republished
`upon receipt of that report
`
`(54) Title: INCLUSION COMPLEX
`
`
`
`08/015695A2|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
`
`6 (57) Abstract: The invention relates to an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydrox—
`N yalkyl—B—cylcodextr‘in, preferably hydroxypropyl—B—cylcodextr‘in. The present invention also relates to an aqueous topical solution
`comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl—B—cylcodextrin,
`preferably hydroxypropyl—B—cy1codextrin and hydroxypropyl methylcellulose in an amount sufficient to enhance the physical stabil—
`
`W0 ity of the solution.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page1
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page1
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`INCLUSION COMPLEX
`
`FIELD OF THE INVENTION
`
`The present invention relates to inclusion complex of olopatadine in cyclodextrin and to aqueous
`
`solutions of olopatadine or its pharmaceutically acceptable salt for topical administration and
`
`process For preparation thereof. =
`
`10
`
`BACKGROUND OF THE INVENTION
`
`Olopatadine hydrochloride is a carboxyl'ic acid derivative ofdoxepin. chemically described as
`
`(Z)-l l-[3-(Dimethylamino) propylidene]-6,l l—dihydrodibenz [b.e]oxepin—2—acetic acid
`
`hydrochloride [Cgli’133 NO;
`
`.HCl], as disclosed in US. Pat Nos.~‘l.87l.8()5 and 4.923.892. both
`
`assigned to Burroughs Wellcome. Olopatadine has antihistaminic and antiasthinatic activity.
`
`Olopatadine hydrochloride is commercially available in the US as 0.1% and 0.2% sterile
`
`ophthalmic solutions under the brand names PATANOL‘“’ and PATADAY" respectively, both
`marketed by Alcon. PATANOLM’ is indicated for the treatment ol"signs and symptoms ol’allergic
`conjunctivitis and the approved ophthalmic solution contains olopatadine hydrochloride
`
`equivalent to 0.1% olopatadine. 0.01% benzalkonium chloride as preservative. dibasic sodium
`
`phosphate. sodium chloride. hydrochloric acid and / or sodium hydroxide (to adjust the pH) and
`
`purified water.
`
`lt has a pH ol’ about 7, and osmolality of about 300mOsm/kg. PATADAY‘" is
`
`indicated for the treatment of ocular itching associated with allergic conjunctivitis and the
`
`approved ophthalmic
`
`solution contains OIOpatadine hydrochloride
`
`equivalent
`
`to
`
`0.2%
`
`olopatadine, 0.01% benzalkonium chloride as preservative, povidone, dibasic sodium phosphate,
`
`sodium chloride, edetate disodium. hydrochloric acid and / or sodium hydroxide (to adjust the
`
`pH) and purilied water. lt has a pH 01" about 7. and osmolality ol'about 300mOsm/hg.
`
`One obstacle l’or preparing olopatadine hydrochloride aqueous solutions lor topical deliver)
`
`is
`
`the stability 01‘ the aqueous solutions ol’ olopatadine hydrochloride over the storage period.
`
`Olopatadine aqueous solutions having a concentrations 01’ 0. l 7%w/v or higher were l’ound to be
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page2
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page2
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`unstable over extended storage periods. The olopatadine hydrochloride precipitates or
`
`crystallizes out ofthe solution when used in concentrations higher than 0. l 7%w/v. Hence, there
`
`is a need for preparing aqueous solutions ofolopatadine hydrochloride containing olopatadine in
`
`concentrations of about 0.17%w/v or greater, which are stable when stored over the shelf life of
`
`the product.
`
`United States Patent No.6,995,186 (Alcon inc., 2006,
`
`the “186 patent) discloses topically
`
`administrable solution composition for treating allergic or inflammatory disorders ofthe eye and
`
`nose comprising olopatadine and a polymeric ingredient, where the polymeric ingredient is a
`
`polymeric physical stability enhancing ingredient consisting essentially of polyvinylpyrrolidone
`
`or polystyrene sulfonic acid in an amount sufficient to enhance the physical stability oi“ the
`
`solution, and wherein the composition does not contain polyvinyl alcohol, polyvinyl acrylic
`
`acid, hydroxypmpyl methyl cellulose, sodium carboxymethyl cellulose, xanthan gum. Polyvinyl
`
`alcohol, polyvinyl acrylic acid, hydroxypropyl methylcellulose, sodium carboxy methyl cellulose
`
`‘J‘I
`
`and xanthan gum have been disclosed in the ”186 patent
`
`to cause physical
`
`instability ol‘
`
`olopatadine solutions.
`
`in order to overcome the physical stability problems associated with olopatadine aqueous
`
`solutions, we have tried various
`
`ingredients selected from hydroxypropyl—B-cyclodextrin
`
`(HPBCD), polysorbate 20, polysorbate 80, propylene glycol, hydroxypropyl methylcellulose
`
`29H)
`
`(HPMC E4M premium),
`
`polyvinylpyrrolidone
`
`K—30,
`
`xanthan
`
`gum,
`
`sodium
`
`, cartmxyrnethylcellulose (Sodium CMC), car-bopol 934P, polyvinyl alcohol and mixtures tlrereol’.
`
`We have now surprisingly found that
`
`stable aqueous
`
`topical
`
`solutions ol’ olopatadine
`
`ix)
`
`hydrochloride can be prepared by forming an inclusion complex with a hydroxyalkyl clodextrin,
`
`preferably hydroxypropyl—B—cyclodextrin (HPBCD). Optionally, hydroxypropyl methylcellulose
`
`(HPMC‘) may be used to stabilize the inclusion complex in the plrarrrraCeutical composition.
`
`[\3
`
`|PR2018—01020 and |PR201 8-01 021, Exhibit 1003 page3
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page3
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`SUMMARY OF THE INVENTION
`
`In one aspect of the invention, there is provided an inclusion complex of olopatadine or its
`
`pharmaceutically acceptable salt and a hydroxyalkyl cyclodextrin, preferably hydroxypropyl-B-
`
`cyclodextrin.
`
`In another aspect of the invention, there is provided an aqueous topical solution comprising a
`
`therapeutically effective amount of olopatadine or
`
`its pharmaceutically acceptable salt:
`
`hyclroxyalkyl B~cylcodextrin,
`
`preferably hydroxypropyl B—cylcodextrin and hydroxypropyl
`
`methyl cellulose in amount sufficient to enhance the physical stability of the solution.
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`The present
`
`invention provides an inclusion complex of olopatadine or its plnirinaceutically
`
`acceptable salt and hydroxyall<yl—[3~cyclodextrin, particularly hydroxyprtnayl—|5—cycloclextrin. The
`
`therapeutically
`invention also provides an aqueous topical solution, comprising> a
`present
`effective amount of olopatadine or
`its pharmaceutically acceptable salt; hydroxyalkyl—B-
`
`cyclodextrin, particularly hydroxypropyl—B-cyclodextrin and hydroxypropyl methylcellulose in
`
`an amount sufficient to enhance the physical stability of the solution.
`
`Unless indicated otherwise, all component concentrations are presented on a %(w/v) basis and all
`
`reference to olopatacline are to olopatadine free base.
`
`The term “in an amount sufficient to enhance the physical stability of the solution“, as used
`
`herein means that the amount of
`
`hydroxyalkyl—[fi-cyclodextrin. particularly hydroxypropyl-B—
`
`cyclodextrin is sufficient to form a complex with olopatadine or its pharmaceutically acceptable
`
`salt and thus keep it in solution, i.e. Prevent its precipitation or crystallization.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page4
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page4
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`According to one embodiment ol’ the present
`
`invention, the aqueous topical solution contains
`.
`
`olopatadine or
`
`its pharmaceutically acceptable salts. Examples
`
`01“
`
`the pharmaceutically
`
`acceptable salts ol’olopatadine include inorganic acid salts such as hydrochloride, hydrobromide.
`sull‘ate and phosphate; organic acid salts such as acetate, maleate. l’umarate, tartrate and citrate:
`
`U1
`
`alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as
`
`magnesium salt and calcium salt; metal salts such as aluminum salt and zinc salt; and organic
`
`amine addition salts
`
`such as
`
`triethylamine addition salt
`
`(also known as
`
`tromethamine),
`
`morpholine addition salt and piperidine addition salt. In a preferred embodiment of the present
`
`invention, the olopatadine for use in the aqueous topical solution is a hydrochloride salt.
`
`in a
`
`1
`
`0
`
`most preferred embodiment of the present invention, the olopatadine hydrochloride salt may be
`
`used in concentrations such that it is equivalent to the blopatadine free base in amount ranging
`
`From about 0.17% to about 0.62%. Preferably, the solution Formulations intended For use in the
`
`eye contain about 0.17% to about 0.25% olopatadine and the solution Formulations intended for
`
`use in the nose contain about 0.35% to about 0.62% olopatadine.
`
`According to one embodiment of the present invention, the aqueous topical solution comprises
`
`cyclodextrin to enhance the physical stability of the solution. Cyclodextrins are a group ol‘
`
`structurally related saccharides which are l‘ormed by enzymatic cyclization of starch by a group
`
`ol‘amylases termed glycosyltransl’erases. Cyclodextrins are cyclic oligosacchz-u‘ides, consisting ol‘
`
`(eilplia—l,¢l)-linked alpha—D—glucopyranose units, with a lipophilic central cavity and a hydrophilic
`
`outer surface.
`
`In aqueous solutions, cyclodextrins form inclusion complexes with many drugs
`
`through a process in which the water molecules located in the central cavity are replaced by'
`
`either the whole drug molecule, or more frequently, by some lipophilic portion of the drug
`
`structure. Once included in the cyclodextrin cavity,
`
`the drug molecules may be dissociated
`
`ls) (J1
`
`through complex dilution, by replacement of the included drug by some other suitable molecule
`
`or, the drug may be transferred to the matrix for which it has the highest al’l’inity. lmportantly,
`
`since no covalent bonds are l‘ormed or broken during the drug—cyclodextrin complex Formation,
`
`the complexes are in dynamic equilibrium with tree drug and cyclodextrin molecules. In solution.
`
`the complexes are usually prepared by addition ol’ an excess amount ol' the drug to an aqueous
`
`cyclodextrin solution. The most common naturally occurring cyclodextrins
`
`are
`
`alpha-
`
`|PR2018—01020 and |PR201 8-01 021, Exhibit 1003 page5
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page5
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`cyclodextrin, B-cyclodextrin and gamma—cyclodextrin consisting ol’ 6, 7 and 8 glucopyranose
`
`units.
`
`respectively and their r. derivatives. B-cyclodextrin appears
`
`to be
`
`the most usel’ul
`
`pharmaceutical complexing agent due to its cavity size, availability and low cost. Examples 01"
`
`cyclodextrin derivatives that may be used in the pharmaceutical compositions of present
`
`U1
`
`invention include the hydroxypropyl derivatives of alpha-, beta» and gamma-cyclodextrin,
`
`sull’oalkylether cyclodextrins such as sulfobutylether beta-cyclodextrin, alkylated cyclodextrins
`
`such as the randomly methylated beta—cyclodextrin, and various branched cyclodextrins such as
`
`glucosyl- and maltosyl beta—cyclodextrin, and the like, and mixtures thereol‘.
`
`The prel‘erred cyclodextrins For use in the present invention include alkyl cyclodextrins, hyclroxy
`alkyl cyclodext‘rin. such as hydroxy propyl beta-cyclod'extrin, carboxy allx’yl cyclodextrins and
`sullioalkyl ether cyclodextrim such as sull‘b butyl ether beta~cyclodextrin Examples ol' suitable
`
`cyclodextrins l‘or use in the present invention non—exclusively include alpha—eyclodextrin; betu~
`cyclotlextrin; gamma-cyclodextrin; methyl alpha—cyclodextrin; methyl beta—cyclodextrin; methyl
`gamma—eyelodextrin; ethyl beta—cyclodextrin; butyl alpha—cyclodextrin; butyl beta—cyclodextrin;
`butyl
`gamma—cyclodextrin;
`pentyl
`gamma—cyclodextrin;
`hydroxyethyl
`beta—cyclodextrin;
`hydroxyethyl gamma—cyclodextrin; 2—hydroxypropyl alpha—cyclodextrin; 2—hydroxypropyl beta—
`cyclodextrin; 2—hydroxypropyl gainma—cyclodextrin; 2—hydroxybutyl beta—cyclodextrin; acetyl
`
`beta—
`propionyl
`gamma—eyelodextrin;
`acetyl
`acetyl beta-cyclodextrin;
`alpha—cyclodextrin;
`eyclodextrin; butyryl beta—cyclodextrin; succinyl alpha-cyclodextrin: succinyl beta-cyclodextrin;
`
`suecinyl
`
`gamma—eyelodextrin;
`
`benzoyl
`
`beta—cyclodextrin;
`
`palmityl
`
`beta—cyclodextrin;
`
`toluenesull‘onyl
`
`beta—cyclodextrin;
`
`acetyl methyl
`
`beta-cyclodextrin;
`
`acetyl
`
`butyl
`
`beta—
`
`cyclodextrin;
`
`glucosyl
`
`alpha—cycloclextrin;
`
`glucosyl
`
`beta—cyclodextrin:
`
`glucosyl
`
`gamma-
`
`cyclodextrin; maltosyl
`
`alpha—cyclodextrin; maltosyl
`
`beta—cyclodextrin; maltosyl
`
`gamma—
`
`IQ U1
`
`cycltit‘lextrin; alpha—cyclodextrin carboxymethylether; beta—cyclodextrin carboxymetliylether;
`
`gamma-eyelodextrin carboxymethylether; carboxymethylethyl beta—cyclodcxtrin; phosphate ester
`
`alplut—cyclodextrin; phosphate ester beta—cyclodextrin; phosphate ester gainma—cyclodextrin; 3—
`
`trimet‘hylammoniurn—Z—hydroxypropyl
`
`beta~cyclodextrin;
`
`sull’obutyl
`
`ether
`
`beta—cyclodextrin;
`
`carboxymethyl alpha—cyclodextrin; carboxymethyl beta—cyclodextrin; carboxymethyl gamma—
`
`cyclodextrin, and combinations thereof. The most preferred cyclodextrin for use
`
`in the
`
`|PR2018—01020 and |PR201 8-01 021, Exhibit 1003 page6
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page6
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`pharmaceutical composition 01’ the present invention is hydroxy propyl beta-cyclodextrin.
`
`In a
`
`prel’erred embodiment of the present invention, hydroxypropyl beta-cyclodextrin may be used in
`
`concentrations ranging from about 0.1% to about 20%w/v ol" the composition, and more
`
`prel‘erably used in concentrations ranging from about 1.0% to about 10% w/v ol‘ the composition.
`
`‘J1
`
`Generally,
`
`l‘or solutions meant
`
`l’or ophthalmic administration prel’erable concentration 01‘
`
`l'or solutions
`hydroxypropyl beta—cyclodextrin is in the range from about 1.0% to about 5%;
`meant 1"or nasal administration, the concentration 01" hydroxypropyl beta—cyclodextrin is in the
`
`range from about 1.0% to about 10%.
`
`10
`
`Olopatadine or its pharmaceutically acceptable salt, according to the present invention, forms an
`inclusion
`complex with
`cyclodextrins,
`particularly
`hydroxyalkyl-B—cyclodextrin, more
`particularly hydroxypropyl—B-cyclodextrin . The term “inclusion complex” as used herein rel’ers
`to a combination of olopatadine or its pharmaceutically acceptable salt as defined above and a
`
`cyclodextrin wherein the olopatadine or its pharmaceutically acceptable salt or a portion thereol'
`is associated with the cyclodextrin. Typically, the olopatadine or its pharmaceutically acceptable
`
`Ux
`
`is included within the cavity of the cyclodextrin, or the host molecule,
`salt or guest molecule.
`wherein the cavity 01’ the cyclodextrin is the space created by the cyclodextrin torous and the
`
`to
`cyclodextrin substituents. The ratio 01" olopatadine or its pharmaceutically acceptable salt
`hydroxypropyl [3—cylcodextrin in the inclusion complex is l'rom about 1:1.05 to about 1:50 by
`weight. The amount 01’ hydroxypropyl
`[fi—cylcodextrin
`present
`in the inclusion complex is
`
`sufficient to enhance the physical stability ol’the olopatadine solution.
`
`According to one embodiment of the present
`invention,
`the composition further
`includes
`hydroxypropyl methylcellulose (HPMC). The hydroxypropyl methylcellulose (HPMC) used in
`the composition acts as a stabilizer for the inclusion complex 01’ hydroxypropyl beta—cyclodextrin
`and olopatadine or
`its pharmaceutically acceptable salt. Various grades 01’ hydroxypropyl
`
`[\3
`
`methylcellulose (available From Dow Chemical, U.S.A under the METHOCEL trademarlx') may
`be used in the present invention. The grades commercially available are categorized depending
`upon the chemical substitution and hydration rates. and may be used in the compositions ol' the
`present
`invention.
`l-lydroxypropyl methylcellulose having a methoxy content ol‘ 19—24 % and
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page7
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page7
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`hydroxypropyl content of 7-l2 % with a fastest
`
`relative rate of hydration is available
`
`commercially under the brand name of Methocel Gracie K. l-lydroxypropyl methylcellulose with
`28—30 "/0 methoxy content andA7—12 % ol' hydroxypropyl content with a faster relative hydration
`
`rate as compared to the above grade is available commercially under the brand name of Mcthocel
`
`'Ji
`
`Gracie E.
`
`l-lydroxypropyl methylcellulose with 27-30 % methoxy content and 4.0 - 7.5 ”/0 of
`
`hydroxypropyl content with a slow relative hydration rate is available as Methocel F grade and
`that with 27.5—31.5 % methoxy content and 0 % hydroxypropyl content and with slowest rate of
`hydration is available as Methocel Grade A. In a preferred embodiment of the present invention,
`hydroxypropyl methylcellulose, a 2%w/v aqueous solution of which has a viscosity of 4000 cps
`at 20"C. and which is commercially available as METHOCEL E4M,
`is used.
`in preferred
`
`embodiments of
`
`the
`
`present
`
`invention,
`
`hydroxypropyl methylcellulose may
`
`be
`
`used
`
`concentrations ranging from about 0.001% to about 5%, and more preferably in concentrations
`
`ranging from about 0.01% to about l % w/v.
`
`The aqueous topical solution of the present invention may include an effective amount of an
`antimicrobial preservative. Examples of pharmaceutically acceptable preservatives that may be
`used in
`the present
`invention include. but are not
`limited to. belt/:ethonium chloride.
`butylparaben, methyl paraben. ethyl paraben. propyl paraben. benzalltonium chloride. cetyl
`pyridinium chloride, thimerosal, chlorobutanol. phenylethyl alcohol. benzyl alcohol‘ potassium
`sorbate, sodium benzoate, sorbic acid and the like and mixtures thereof. The preferred
`
`preservative for the aqueous topical solution of the present invention is benzalkonium chloride.
`
`It may be used in an amount ranging from about 0,005% to about l%w/v.
`
`[\3
`
`invention may include an effective amount of a
`The aqueous topical solution of the present
`chelating agent. Chelating agents remove trace amounts of metal ions such as iron. copper and
`lead and act as antioxidants, as otherwise these heavy metals catalyze oxidation reactions.
`
`Presently preferred chelating agents include different salts of edetic acid. These non—exclusively
`include edetate disodium, edetate calcium disodium, edetate tetrasodium, edetate trisodium. and
`the like and mixtures thereof. The preferred chelating agent for the aqueous topical solution of
`
`|PR2018—01020 and |PR201 8-01 021, Exhibit 1003 page8
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page8
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`the present invention is disodium edetate. It may be present in the concentrations ranging from
`
`about 0.005% to about 0.1% w/v.
`
`The aqueous topical solution of the present invention may further include an effective amount ol‘
`
`U1
`
`a tonicity agent. Examples of tonicity agents that may be used in the aqueous topical solution ol‘
`
`the present invention include all pharmaceutically acceptable and pharmacologically inert water—
`
`soluble compounds referred to in the pharmacopoeias such as United States Pharmacopoeia, as
`well as in Remington: The Science and Practice of Pharmacy; edition 19; Mack Publishing
`
`Company, Easton, Pennsylvania U995). Preferred tonicity agent is sodium chloride, which may
`
`be added in an amount which renders the solution isoosmotic. The aqueous topical solution is
`
`intended to be administered as nasal solution or eye drops. The osmolality may be adjusted
`
`preferably between 150 to 450 mOsm, and more preferably between 250 to 350 mOsm.
`
`l
`
`The aqueous topical solution-of the present
`
`invention may include an effective amount of
`
`buffering agent. The buffering agents are included to minimize any change in pH during shelf
`
`life of the aqueous topical solution. Examples of buffering agents include, but are not limited to.
`
`lactic acid, citric acid, tartaric acid. phosphoric acid, acetic acid, hydrochloric acid. nitric acid.
`
`tromethamine, sodium or potassium metaphosphate, sodium or potassium phosphate. dibasic
`
`sodium phosphate dodecahydrate,
`sodium or potassium acetate, ammonia. sodium carbonate.
`sodium or potassium hydroxide, dibasic sodium phosphate, sodium borate. and the like and
`
`mixtures thereof. Strong mineral acids like hydrochloric acid or strong bases such assodium
`
`hydroxide may be used for adjusting pH. The aqueous topical solution intended for ophthalmic
`
`administration has a pH 4 to 8, preferably pH of 6.5 to 7.5, and most preferably a pH of 6.8 to
`
`7.2. The aqueous topical solution intended for nasal administration has a pH ol‘3.0 to 6.0. and
`
`Ix) (J1
`
`most preferably a pH of3.5 to 5.0.
`
`The aqueous topical solution of the present
`
`invention may optionally include an effective
`
`amount ofan antioxidant. The antioxidant may be one or more antioxidants. reducing agents and
`
`antioxidant synergist, and may be selected from acetyl cysteine, alpha tocopherol acetate.
`
`d—
`
`alpha tocopherol, dl—alpha tocopherol, ascorbyl palmitate, butylated hydroxyanisole (BHA),
`
`|PR2018—01020 and |PR201 8-01 021, Exhibit 1003 page9
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page9
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`butylated hydroxytoluene (BHT), cysteine, cysteine hydrochloride, propyl gallate, ascorbic acid,
`
`calcium ascorbate. calcium bisulphate, calcium sulphite, ascorbic acid,
`
`isoascorbic acid.
`
`potassium metabisultite, sodium ascorbate, sodium bisulphate, sodium metabisulphite. sodium
`
`sulphitc. sodium thiosulphate.
`
`thioglycerol, citric acid , edetic acidtlz‘DTA) and its salts.
`
`U1
`
`liytlroxyquinoline sulphate, phosphoric acid, sodium citrate and tartaric acid. The antioxidants
`
`may be used in amounts conventional to the pharmaceutical art.
`
`The aqueous topical solution of the present
`
`invention may optionally include an effective
`
`amount ol‘viscosity enhancer. An increase in viscosity ol’ topical solutions will result in a longer
`
`10
`
`residence time in eye or nose, providing a longer time for drug absorption and effect. The list 01“
`
`viscosity enhancers that are conventionally used for
`
`topical
`
`solutions are given in
`
`the
`
`pharmacopoeias such as United States Pharmacopoeia, as well as in Remington: The Science
`and Practice of Pharmacy; edition 19; Mack Publishing Company, Easton, Pennsylvania (1995).
`
`The viscosity enhancers may be used in concentrations conventional to the pharmaceutical art.
`
`The aqueous topical solution oFthe present invention is chemically stable. The term “chemically
`
`stable“ as used herein means that the aqueous topical solution when stored on the shell" Tor up to
`
`two years has less than 2% total degradation products as determined by the area normalization
`
`method. The chemical stability may be assessed by accelerated stability testing. The aqtrcous
`
`topical solution ol~ the present. invention may be stored in a closed container at 30%" / 05%
`relative humidity or 400C / 75% relative humidity or 2—8”C (refrigeration condition) and analyzed
`
`at one month duration for tip to three months or six months.
`
`it
`
`is generally accepted that a
`
`product is stable on the shell“ over a period ol’ two years, il“ the product is stable l’or three months
`
`at an accelerated stability test condition ol’ 40“C / 75% relative humidity.
`
`[Q 'J}
`
`The term “physical stability” as used herein means that when aqueous topical solution ol" the
`
`present invention are stored in a closed container crystals ofolopatadine do not appear.
`
`The chemical stability is assessed by evaluating the percent total degradation ol‘ olopatadine
`
`aqueous topical solutions that are subjected to accelerated stability test conditions and ambient
`
`C)
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page10
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page10
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`conditions using high performance liquid chromatography (I-IPLC). The chromatographic
`
`conditions For analyzing the degradation of olopatadine and the procedure for calculating the
`
`percent total degradation products in olopatadine aqueous topical solution is given below:
`
`(‘olumn
`
`U1
`
`Flow rate
`
`Temperature
`
`Detection
`
`: l-lypersil BDS Cs (250 X 4.6)
`
`: 1.0 ml/min
`
`: Ambient
`
`: 210 nm
`
`Concentration
`
`: 50/65 ppm
`
`Injection volume
`
`: 20p]
`
`10
`
`Run time
`
`: 40 min
`
`Mobile Phase
`
`: Buffer: Acetonitrile (720 : 280)
`
`Buffer : 6.8 gm KI—lgPO4 is dissolved in lOOOml of water and the solution is
`
`adjusted to a pH of 4.5 with orthophosphoric acid.
`
`Retention time
`
`: 10.5 min
`
`Diluent
`
`: Mobile phase
`
`Standard preparation : 50/65 mg olopatadine HCl is dissolved in lOO ml with mobile phase.
`
`A sample ofS ml is diluted to 50 ml with mobile phase
`
`Test preparation
`
`: 2 ml 01‘ the olopatadine HCI solution is diluted with 200 ml oi~ mobile
`
`phase
`
`The percent total degradation products in the olopatadine aqueous topical solution is calculated
`
`by area normalization method (excluding peaks from placebo and diluent,
`
`il“ any) from the
`
`chromatogram obtained by
`
`injecting 20p] of
`
`test preparation as described above
`
`in
`
`chromatographic conditions
`
`for analyzing degradation of olopatadine. The
`
`formula
`
`tor
`
`calculating the percent total degradation products in olopatadine aqueous topical solution is
`
`given below:
`
`"/0 individual degradation product =
`
`-------------------------------------------------------------- X 100
`
`Peak area of individual degradation product
`
`Total area ol’all the peaks
`
`10
`
`IO U1
`
`10
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page11
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page11
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`U1
`
`10
`
`% Total degradation products
`
`“
`
`Sum of all % individual degradation products
`
`For l'inished dosage forms (For example - solutions) the value of“ percent individual degradation
`
`product should not be more than 1% and the percent total degradation products should not be
`
`more than 2%. A value of percent total degradation products lesser than 2% in the aqueous
`
`topical solution ot‘the present invention is considered to be acceptable.
`
`According to one embodiment ol’ the present
`
`invention.
`
`the aqueous topical solution may be
`
`prepared by the following process:
`
`a. Dissolving hydroxypropyl-B—cyclodextrin(HPl3CD) in water For injection till clear solution
`
`is Formed.
`
`b. Dissolving tonicity agent, buffering agent, chelating agent and antimicrobial preservative in
`
`the bulk solution ol'istep (a) and stirring to get clear solution.
`
`c. Dissolving olopatadine hydrochloride in water for injection and adding to the solution ol
`
`step (a).
`
`d. Adjusting pH of the solution between 3.5-5.0 for nasal solution. and between 6.8—7.2 tor
`
`e.
`
`l“.
`
`Ophthalmic solution with O.IN hydrochloric acid and (MN sodium hydroxide.
`
`Final adjustment ot‘volume with water for injection and measuring pH.
`
`Filtering ol’ the solution through 2pm prefllter and then through 0.2th nylon 66 membrane
`
`filter; and transl‘erring the solutions to sterile containers.
`
`The aqueous topical solution ol‘ the present invention may be lormulated to be diSpensed in
`
`suitable containers as drops, sprays, metered sprays, aerosols and metered aerosols. The aqueous
`
`[Q U1
`
`topical solution to be delivered as nasal spray may be filled in containers titted with a spray
`
`pump with or without a metering valve. The aqueous topical solution to be delivered as aerosol
`
`may be filled into canisters suitable for delivering pharmaceutical aerosols. Canisters generally
`comprise a container capable of withstanding the vapour pressure of the propellant used such as
`
`a plastic or plastic-coated glass bottle, or preferably a metal can, for example an aluminium can
`
`which may optionally be anodized,
`
`lacquer—coated and / or plastic-coated, which container is
`
`11
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page12
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page12
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`closed with a metering valve. The metering valves are designed to deliver a metered amount ol‘
`the atlueous solution per actuation, and have a gasket to prevent leakage ol’ propellant through
`
`the valve. In a prel’erred embodiment oFthe present invention, the aqueous topical solution is
`
`packed in opaque plastic or glass containers.
`
`In a more preferred embodiment ol’ the present
`
`inventiorL the container For an ophthalmic solution is an opaque, white low-density polyethylene
`
`container that has been sterilized using ethylene oxide like lupolen bottle. In another prel‘errcd
`
`embodiment ol‘ the present invention, the container For a nasal solution is a U.S.P type I amber
`
`color glass container equipped with a suitable nasal spray pump.
`
`l0
`
`it will be understood by those of skill
`
`in the art that numerous and various modifications can be
`
`made without departing from the spirit of the present invention. Therefore, it should be clearly
`understood that the following examples are illustrative only and are not intended to limit the
`
`scope of the present invention.
`
`
`
`Ix.)‘
`
`Ln
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page13
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1003 page13
`
`

`

`WO 2008/015695
`
`PCT/IN2007/000199
`
`COMPARATIVE EXAMPLES A-M
`
`The compositions shown in table 1 and table 2 below were prepared and subjected to stability
`
`studies
`
`l’or evaluating the physical stability. The vials were studied l’or stability at
`
`two
`
`5
`
`temperature conditions: one at room temperature (250 i
`
`2°C) and the other at refrigeration
`
`temperature (2~8”C) condition.
`
`_|
`
`
`
`0.527
`
`0.527
`
`0.527
`
`0. 527
`
`-
`
`methylcellulose
`
`_
`
`_
`
`-
`
`_
`
`—
`
`
`premium)
`
`—l
`
`
`
`.
`
`O 10
`
`,,
`.x.
`
`5
`
`O
`
`.
`0. 0
`
`l
`
`
`
`Table 1
`
`
`Com arative Examples A-H
`
`Ingredients
`C
`D
`E
`A
`B
`F
`(J
`H
`Concentration (%w/v)
`
`Olo J'ttadine
`~- —I
`j—
`—|
`l‘
`.
`0.527
`27 0.665
`hydrochloride
`-
`Polysorbate 20
`Polysorbate 80
`.
`‘
`.
`
`Pr_pyleneJLUlycol
`0.05
`
`
`l-lydroxypropyl—l
`(29l0 E4M
`J_
`Polyvinyl
`2.00
`pyrrolidone K—
`30
`0.30
`Sodium chloride
`0
`q
`Benzalkonium —'
`'0“
`O 0
`chloride (50% )
`_
`0 0|
`_
`Disodium
`L_'
`|_
`cdetate
`_‘_
`
`_l_
`Dibasic sodium
`l—_
`phosphate
`0.06
`0.50
`0.20
`__l
`lindecahydrate L
`_l_
`pH 3.5 —l
`31;
`pH 4.5
`pH 4.5
`pl—l 4.5
`pH 4.5
`N-Oll /llCl
`pH 4.5
`pH 4.5
`—5.0
`_5'0
`-5.0
`—5.0
`—5.0
`N“
`~5.0
`i—so +6.0
`l—Water lor
`q.leO q.leO q.le0
`q.leO q.leO q.s100
`q.310
`qsIOO
`
`ml
`ml.
`ml
`0 ml
`ml
`lnjection
`
`
`
`0.50
`
`0.25
`
`0.25
`
`0. l 5
`
`0.10
`
`10
`
`13
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1003 page14
`
`
`
`
`
`
`
`
`
`
`
`
`-

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket